Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: OBT076, a CD205-directed antibody-drug conjugate
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Oxford BioTherapeutics Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT04064359
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai, Los Angeles, California, United States
🇺🇸UCLA, Santa Monica, California, United States
News
No news found